Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
Next-generation sequencing can identify molecular alterations in glioma: are we ready for targeted treatments?
Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking
Building a lasting foundation for precision oncology
While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients.
Overall survival data further support sacituzumab govitecan in HR+/HER2– metastatic breast cancer
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
How to integrate tebentafusp in the checkpoint-based clinical management of patients with uveal melanoma?
Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
What is the state of play for molecular profiling in gynaecological malignancies?
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential
Managing ovarian cancer in the PARP inhibitor era
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022